JMP® Clinical adds risk-based monitoring; JMP®
Genomics extends tools for prediction of outcomes
Evaluate risk efficiently, limiting the need for on-site monitoring
that can account for 30 percent of clinical trial costs.
Easily identify errors and fraud pertaining to individual subjects and
Analyze data for safety issues at the trial level and for individual
Identify and analyze events, findings and interventions.
Reveal patterns and predict outcomes from clinical trial data.
Facilitate information sharing among colleagues.
CARY, N.C.--(BUSINESS WIRE)--
Risk-based monitoring methods new in JMP®
Clinical software from SAS limit costly on-site audits of source
data during clinical trials while protecting study participants. JMP
Genomics now offers enhanced capabilities for analyzing data related
to agriculture, pharmacogenomics, biotechnology and more.
JMP Clinical 5.0 and JMP Genomics 7.0 were introduced today at the
Bio-IT World Conference and Expo in Boston.
Both solutions integrate sophisticated SAS® statistical
algorithms with interactive JMP data visualization to make discovery
from life sciences data faster and easier. JMP
is a business unit of SAS,
the leader in business
analytics software and services.
“This new version of JMP Clinical enables our customers to effectively
monitor and statistically analyze safety and efficacy data. More than
that, it reduces risk and identifies possible misconduct at the patient,
site or country level,” said JMP Product Manager Geoff Mann. “For the
first time, all of that is under one hood."
New and enhanced features in JMP Clinical 5.0:
JMP Genomics 7.0 includes methods to:
Correlate clinical phenotypes with rare or common genetic variants.
Analyze gene expression, miRNA or metabolomics data for differential
values between experimental classes.
Normalize and analyze NGS data with a wide variety of options.
Discover biomarker profiles from high-dimensional data sets through
cross-validation and model comparisons.
Create pathway scores from gene expression data and explore with ANOVA
or clustering methods.
What customers are saying:
“From my perspective, JMP Clinical has become absolutely essential to an
efficient, cost-effective drug-development process.” Mark Williams, Vice
President and CIO, Applied Clinical Intelligence.
“There’s no way I could have done this work with typical statistical
programs and methods. JMP Genomics was key to its success.” Ray Langley,
Lovelace Respiratory Research Institute, author of a 2013 article in
Science Translational Medicine about a study that led to development of
a blood test for early identification of life-threatening forms of
Fully functional 30-day trials of JMP
Clinical and JMP
Genomics are available for free on the JMP website.
SAS created JMP in 1989 to empower scientists and engineers to explore
data visually. Since then, JMP has grown from a single product into a
family of statistical discovery tools, each one tailored to meet
specific needs. John Sall, SAS co-founder and Executive Vice President,
heads the JMP business unit.
SAS is the leader in business
analytics software and services, and the largest independent vendor
in the business intelligence market. Through innovative solutions, SAS
helps customers at more than 70,000 sites improve performance and
deliver value by making better decisions faster. Since 1976 SAS has been
giving customers around the world THE POWER TO KNOW®.
SAS and all other SAS Institute Inc. product or service names are
registered trademarks or trademarks of SAS Institute Inc. in the USA and
other countries. ® indicates USA registration. Other brand and product
names are trademarks of their respective companies. Copyright © 2014 SAS
Institute Inc. All rights reserved.
Anne Bullard, 919-531-6617